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Objective. To determine whether there is a diﬀerence in intraoperative bleeding with inhalational versus noninhalational an-
esthetic agents for patients undergoing suction dilatation and curettage for ﬁrst-trimester induced abortion. Methods. 'is is an
IRB-approved retrospective chart review of the electronic medical records of patients undergoing induced abortion at gestational
ages between 5 0/7 and 14 0/7 weeks of pregnancy at the New York City Health + Hospitals/Metropolitan. 'e records of 138
patients who underwent suction dilatation and curettage for induced abortion between June 2012 and June 2014 were reviewed for
an association between anesthetic technique and intraoperative hemorrhage. Twenty patients received inhalational anesthetic
agents, while 118 received intravenous anesthetics. Blood loss was estimated by the operating gynecologists. Results. 'e mean
intraoperative blood loss for inhalational anesthetics (113.6ml) was signiﬁcantly higher than with noninhalational agents
(40.2ml) (p � 0.007). Age, body mass index, and gestational age were not statistically diﬀerent between the groups; the number of
methylergonovine doses at induced abortion trended higher with inhalation anesthetics. Conclusions. 'e diﬀerence in blood loss
between the two types of anesthetic techniques was statistically signiﬁcant. 'ese ﬁndings may be important for patients with
signiﬁcant anemia or at an increased risk of bleeding, such as those with unrecognized coagulopathies.
1. Introduction
Over one million pregnancies result in induced abortion in
the United States each year [1]. Recent studies have shown
that the mortality risk from an induced abortion is 0.7 per
100,000 [2]. Minor complications have dropped to an es-
timated eight per 1000 abortions by 1990, and major
complications have decreased to 0.7 per 1000 induced
abortions [3]. Both hemorrhage and anesthetic complica-
tions have been the leading causes of abortion-related
mortality. Hemorrhage is the leading cause of mortality
during second-trimester induced abortions, and is the
second leading cause of mortality in ﬁrst-trimester induced
abortions, following infection [4]. Recent studies have
documented the continued importance of postabortion
hemorrhage; a conservative estimate of the incidence of
hemorrhage of clinical consideration is approximately 1% of
procedures [5, 6]. A large study reported the incidence of
hemorrhage requiring blood transfusions at 0.4% [7].
Many studies have compared the eﬀects of volatile and
intravenous anesthetic agents on isolated uterine myome-
trium in vitro [8–10]. 'e use of volatile agents, such as
halothane and enﬂurane, has led to signiﬁcantly increased
blood loss. All inhalational agents were used at 1.5 MAC and
above, and such concentrations would likely be avoided in
current practice. 'e following anesthesia concentrations
were noted in a Hall et al. study: patients received fentanyl
onemicrogram/kilogram (kg), followed by an induction
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dose of propofol (2-3mg/kg); then a propofol infusion was
started using a standard regimen of 12mg/kg/h for 10min
and then 9mg/kg/h for 10min; they also received bolus
doses of propofol (20mg) if anesthesia was too light; patients
breathed 66% nitrous oxide in oxygen via face mask; in the
second group, after preoxygenation, patients received fen-
tanyl one microgram/kilogram followed by an induction
dose of propofol (2-3mg/kg); anesthesia was maintained
with 1% isoﬂurane (measured concentration) and 66% ni-
trous oxide in oxygen via face mask; isoﬂurane concentra-
tion was increased by 0.5% and a further 0.5% if necessary,
using a concentration of 1% isoﬂurane if the anesthesia was
too light and when the patient was stable [11]. Few in-
ternational studies have compared volatile anesthetics with
propofol for minor gynecologic procedures, including in-
duced abortion [12]. One Canadian study by Nathan et al.
was prematurely terminated in a prospective randomized
study comparing the cost of sevoﬂurane and propofol during
ambulatory induced abortion procedures due to an un-
acceptable increase in bleeding in the sevoﬂurane group [13].
Another prospective study completed in Wales by Hall et al.
found signiﬁcantly more intraoperative blood loss with the
use of inhaled isoﬂurane than with intravenous propofol
[11].'e existing literature is approximately 20–30 years old,
and the dosages cited are no longer recommended. 'e
current study describes the up-to-date use of these anesthetic
agents for this important patient group.
Also, one of the authors (MAI) was a coauthor in a major
recent study that examined the frequency of unrecognized
abnormal coagulation indices in patients who had been
prescreened and deemed negative by their history and
physical ﬁndings for coagulation defects [14]. A relatively
high incidence of unanticipated abnormal coagulation in-
dices was observed and prompted the authors to report
ﬁndings on the possible adverse inﬂuence of the anesthetic
intervention on some members of a patient population that
may be more vulnerable to excessive bleeding, such as
during an induced abortion.
2. Materials and Methods
Following Institutional Review Board (IRB) approval (L-
11,256) from New York Medical College, New York City
Health + Hospitals/Metropolitan, and the New York City
Health + Hospitals, a single institution retrospective chart
review was conducted. Patients who had complete anesthetic
records and underwent suction dilatation and curettage for
induced abortion from 5 0/7 weeks to 14 0/7 weeks of
gestation between June 1, 2012, and June 1, 2014, were
evaluated. A waiver of informed consent was obtained per
IRB guidelines due to the retrospective chart review.
Sedation state and/or general anesthesia was maintained
with intravenous (IV) propofol, inhaled sevoﬂurane, or
inhaled desﬂurane. Inhaled sevoﬂurane and desﬂurane were
grouped together for data analysis under inhalational agents.
'e type of anesthetic agent used was based on the pref-
erence and judgment of the attending anesthesiologists. 'e
Department of Anesthesiology for New York City Health +
Hospitals/Metropolitan clinical guidelines recommend the
use of inhalational agents for induced abortions and di-
latation and curettage procedures at equal to or less than 0.75
MAC of the inhalational agent of choice. Complete anes-
thetic records were available for review, including the
documentation of the types of anesthetics used and esti-
mated blood loss. Subjects were excluded from review if
there was a lack of hospital records for both anesthetic and
blood loss documentation.
'e following factors were recorded and analyzed in
relation to anesthetic choice and intraoperative blood loss:
age, weight, gravidity, parity, past medical history (with an
emphasis on a history of bleeding disorders) and past
surgical history, gestational age determined via ﬁrst-
trimester ultrasound, preoperative medications, intra-
operative medications, postoperative medications, and the
American Society of Anesthesiologists (ASA) status.'e two
coauthors (CAC and AB), who were the operating surgeons,
and research assistants (GH and DC), performed the chart
review. Data were transferred on a piloted form on an
electronic database by the secondary author (GH). 'e
accuracy of the original data transfer and recording was
conﬁrmed by the primary author (CAC).
'e intraoperative blood loss was estimated by two at-
tending gynecologists (AB and CAC), who performed these
procedures.'eymade a visual estimation of blood collected
in a vacuum canister, which was marked oﬀ in milliliters and
accurately recorded. 'eir estimations were systematically
similar to each other in the assessment of blood loss. 'e
gynecologic surgeons did not measure the postprocedure
blood loss. For ﬁrst-trimester induced abortions, the vacuum
canister includes amniotic ﬂuid and products of conception,
which is in small amounts when compared to procedures at
later gestational ages. 'e mean gestational ages were the
same in the two treatment groups, which did not change the
outcome of the estimated intraoperative blood loss
signiﬁcantly.
Patients varied in their past medical and surgical his-
tories. Preoperative complete blood counts (CBC) were
obtained in most patients with only two patients having
a preoperative hemoglobin level of less than 10 grams per
deciliter. Each patient was given an oral azithromycin two
gram dose from zero to 24 hours prior to procedure and
a prescription for oral methylergonovine 0.2mg every six
hours for four days following procedure. Midazolam and
fentanyl were used in most subjects in conjunction with the
anesthetic agent of choice.
Statistical analyses were carried out using StatMost ©
software (Dataxion Corp., Los Angeles, California). A com-
parison of blood loss in relation to anesthetic technique was
done using Student’s t-test since the data in both groups were
normally distributed. 'e possible contribution of diﬀerences
in the age of the patient, body mass index (BMI), or gesta-
tional age were analyzed with the nonparametric Mann–
Whitney test since some of the data were not normally
distributed. 'e need for the use of methylergonovine in the
operating room or in the postanesthesia care unit as a possible
confounder was analyzed with the Fisher’s exact test.
A two-tailed p value of 0.05 or less was taken as
a measure of statistical conﬁdence for all analyses.
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3. Results
A total of 197 patients had ﬁrst-trimester induced abortions
in the time frame of the study. Of these, 182 patients received
a prescription for methylergonovine postoperatively on
discharge from the hospital. One hundred thirty-eight
subjects, with electronic medical records and complete
anesthesia records and estimated blood loss, were analyzed.
Subjects overall ranged from 15 to 43 years; gestational ages
ranged from 41 to 89 days; and BMI indexes ranged from 17
to 48 kg/m2.'e two groups of patients showed no statistical
diﬀerences in regard to these three parameters (Table 1).
Estimated intraoperative blood loss ranged from 5 to
350ml. 'e mean estimated blood loss for the inhalational
anesthetics was 113.6ml, while the mean estimated blood
loss for the use of intravenous anesthetics was 40.2ml. 'is
diﬀerence was statistically signiﬁcant (p< 0.007; Figure 1).
Twenty percent (4 of 20) of the group receiving in-
halation anesthetics received intraoperative doses of
methylergonovine compared to 10.2 percent (12 of 118) in
the IV anesthetic group (not statistically diﬀerent; p � 0.250)
(Figure 2).
Nine patients had a suction dilation and curettage at
a gestational age of greater than 77 days and received
Laminaria japonicum (Cooper Surgical, Inc, Trumbull, CT
06611, USA) for mechanical cervical dilatation at approxi-
mately 24 hours before the procedure. Postoperative com-
plete blood counts (CBCs) were not done. None of the
patients demonstrated symptoms of acute blood loss anemia
or required transfusion.
4. Discussion
Our study found a statistically signiﬁcant diﬀerence in the
blood loss in patients receiving inhalational versus non-
inhalational agents. Although total blood loss in both groups
was not excessive, the greater blood loss with inhalation
anesthetics may be of importance when approaching the
patient at an increased risk of uterine bleeding during gy-
necologic procedures, such as those with recognized or
unrecognized coagulopathies. Although increasingly rare,
uterine hemorrhage is the leading cause of mortality during
second-trimester induced abortions, and is the second
leading cause of mortality in ﬁrst trimester induced
abortions.
'e risk of unrecognized coagulation issues was docu-
mented in a multicenter study involving more than one
million patients that included data on the incidence of
unanticipated abnormal prothrombin (PT) or activated
partial thromboplastin time (aPTT) coagulation indices in
presurgical testing [14]. As noted above, our institution was
a participant in that study. In patients that did not have
history and physical ﬁndings or laboratory results that would
prompt either a PT test (i.e., history of abnormal bleeding,
warfarin therapy, clotting factor deﬁciencies, and liver
disease) or aPTT test (i.e., on heparin therapy, hemophilia,
evidence of lupus anticoagulant factor, or von Willebrand
disease), 6.6% of the patients had abnormal PT values and
7.1% had abnormal aPTTs [14].
Optimizing anesthetic choice and addressing hemor-
rhage risk factors prior to a procedure may reduce the in-
cidence of hemorrhage-relatedmorbidity andmortality. Our
results suggest that patients with anemia or with increased
risk of bleeding should not be given inhalational anesthesia
unless other factors outweigh this increased risk of bleeding.
Other intraoperative options to address bleeding are the use
of intracervical vasopressin or intravenous oxytocin (al-
though the latter depends on the gestational age, the
presence of oxytocin receptors, and the timing of the
pregnancies) in patients thought to be at increased risk of
bleeding during the induced abortions. 'e current study
lends emphasis to the danger that patients with compro-
mised hemostasis might face if treated with inhalational
anesthesia. It is one more considerable factor for the an-
esthesiologist when making individualized decisions on
which anesthetic technique to utilize.
In vitro studies may point to a mechanism behind these
results. A study by Paull and Ziccone revealed the depressant
eﬀects of volatile anesthetics on isolated human uterine
muscle contractility [15]. It has been hypothesized that
inhalational anesthetics result in the relaxation of uterine
muscle and predispose the gravid uterus to hemorrhage.
Micks et al. also demonstrated that the use of sevoﬂurane
slightly resulted in a measured blood loss of over 300ml
(considered to be excessive) or increased the frequency of
interventions to treat hemorrhage in patients who un-
derwent induced abortions at 18 to 24weeks of gestation,
although this was not statistically signiﬁcant [16]. 'is study
was also underpowered to detect these diﬀerences. Also, at
higher gestational ages, such as when induced abortions
were performed in the Micks et al. study, there is a higher
risk of bleeding and excessive blood loss [16].'e diﬀerences
in blood loss between the inhalational agents and non-
inhalational agents were still noted in patients who received
more doses of methylergonovine in our study since halo-
genated inhalation anesthetics exert a direct relaxation of the
myometrium [8–10]. 'is opposes, in a functional (physi-
ological) manner, the myometrial contractile eﬃcacy ex-
pected from methylergonovine and, thus, leads to more
blood loss.
One limitation of this study was that the gestational ages
of patients who underwent induced abortions were at or
below 14 and 0/7 weeks. Atony has been associated with an
increased risk of hemorrhage in a review of 3000 surgical
abortions in the second trimester in patients that were of
older maternal age and greater gestational ages [17]. Another
limitation was the measurement of blood loss, which al-
though carefully estimated by two attending gynecologists
performing the procedures, is known to have inherent
problems with accuracy. Another limitation of our study was
that the gynecologic surgeons were not blinded for the
choice of anesthetic provided.
In view of the relatively small number of patients rep-
resented in the group receiving inhalation anesthetics and
the lack of statistically signiﬁcant diﬀerences between the
patient groups for factors that might be expected to inﬂuence
blood loss (i.e., age, BMI and gestational age; Table 1), we
conducted power analyses on these three comparisons to
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evaluate the possible risk of Type II errors. Assuming the
same variances in the comparisons and preserving the
same ratio between the numbers in the two groups, it
would require a total sample of 3,414 patients to bring the
small dierence between the mean values for age to
statistical signicance. Likewise, 3,567 patients would be
required for a statistical dierence between the groups for
BMI, and 9,540 patients required for the dierence in
gestational age. ese analyses are supportive that our
ndings are not diminished by Type II errors. And, as
noted above, the nding of a statistically signicant
dierence in blood loss between the two groups (Figure 1)
is strengthened by the fact that the data in both groups
were normally distributed and not inuenced by several
extreme cases of blood loss.
e group that received inhalation anesthetics had
greater blood loss despite the fact that they had ap-
proximately twice the frequency of use of doses of
methylergonovine than the group receiving IV anes-
thetics (Figure 2). is dierence in frequency did not
reach statistical signicance; however, as part of our
power analyses, we found that if the total patient number
(with the same variances and ratio of IV to inhalation
anesthetic) was three times as large as in the present data,
the trend toward higher use of methylergonovine would
reach a statistical dierence.
In summary, choice of the anesthetic should be consid-
ered in all gynecologic procedures, particularly for induced
abortions at both early and late gestational ages, to reduce the
potential risk of morbidity andmortality. Our ndings extend
the advisability of avoidance of inhalational anesthetics for
induction of abortion where possible. Anesthesiologists, in
particular, should consider the increased risk of bleeding
associated with inhalation anesthesia over noninhalational
agents when individualizing the anesthetic technique for
patients presenting for induced abortion, especially those with
anemia or increased risk of bleeding. is is emphasized by
the relatively high frequency of abnormal coagulation indices
that were found in the large multicenter study noted above in
patients whowere cleared on the basis of standard criteria that
would prompt PT or aPTT testing.
Data Availability
e data used to support the ndings of this study are
available from the corresponding author upon request.
Disclosure
is paper was presented as an e-poster at the American
College of Obstetricians and Gynecologists Annual Clinical
and Scientic Meeting, San Diego, May 6, 2017.
Table 1: Absence of dierences in demographic factors between the anesthetic treatments.
Intravenous anesthetic, n  118 Inhalation anesthetic, n  20 Group comparisons
Mean (SE) Mean (SE) p value
Age (year) 27.8 (0.6) 28.6 (1.4) 0.444
BMI (kg/m2) 27.0 (0.6) 26.2 (1.1) 0.749
Gestational age (days) 58.6 (1.3) 57.4 (2.8) 0.470
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anesthetic
Inhalation
anesthetic
p = 0.007
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Figure 1: Comparison of blood loss between anesthetics.
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Figure 2: Comparison of perioperative methylergonovine doses.
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